Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-ACT319 in FAP-expressing pancreatic ductal adenocarcinoma and other solid tumors
ACTRN12626001201369Phase 2Not yet recruiting
- Sponsor
- Actithera
- Start
- Oct 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of 177Lu-ACT319 in pancreatic adenocarcinoma (PDAC), biliary cancer and Nonhematologic neoplasms (5 arms), sponsored by Actithera. Primary endpoints: Safety and tolerability; estimate maximum tolerated dose and/or define recommended dose for expansion, Objective response rate and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
177Lu-ACT319
03
Conditions
pancreatic adenocarcinoma (PDAC)biliary cancerNonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12626001201369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001201369.